YCYen Tzu Chen

Yen Tzu Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yen Tzu Chen has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ‘It helps me stay on track’: patient experiences using a mobile app for self-management of systemic sclerosis with a focus on fatigue in women

    by Yen T Chen, Alexandra E Harper, Mary Alore, Elizabeth Haro, John T Morris, Dinesh Khanna, Susan L Murphy

    Objectives: Fatigue is common and burdensome in people with systemic sclerosis (SSc), significantly impacting daily functioning and quality of life. Yet, it remains inadequately addressed in clinical care. This study aimed to explore participants’ experiences using the RENEW (Resilience-building Energy Management to Enhance Well-being) mobile app as a standalone self-paced intervention without peer coaching for fatigue self-management. Methods: Semi-structured interviews were conducted with participants with SSc following completion of the 12-week RENEW mobile app intervention. Interviews were analysed using RADaR (Rigorous and Accelerated Data Reduction) technique in combination with thematic content analysis. Results: Fifteen women were included in the analysis (mean age 56 years ± 10), which reflects the higher prevalence of SSc among women. Among participants, 53% had limited SSc, while the remaining had diffuse SSc or overlap, and 40% had been diagnosed with SSc for less than 5 years (short duration). Four themes were identified: (1) the RENEW app and its features were intuitive; (2) the RENEW app’s content enhanced the learning experience; (3) the RENEW app became a partner to support SSc self-management and (4) refinements to the app could enhance the patient experience. Conclusion: The RENEW app was perceived as a relevant and user-friendly tool for supporting fatigue self-management in SSc. Findings suggest that a standalone app-based approach may offer a scalable option for fatigue self-management in SSc, while also highlighting areas for refinement to improve engagement and long-term use. Trial registration: clinicaltrials.gov, NCT07402863.

  • Open Access

    A Scoping Review on Artificial Intelligence–Supported Interventions for Nonpharmacologic Management of Chronic Rheumatic Diseases

    by Nirali Shah, Alexis Castellanos, Yen Chen, John Piette, Amy Bucher, Susan Murphy

    This review summarizes artificial intelligence (AI)‐supported nonpharmacological interventions for adults with chronic rheumatic diseases, detailing their components, purpose, and current evidence base. We searched Embase, PubMed, Cochrane, and Scopus databases for studies describing AI‐supported interventions for adults with chronic rheumatic diseases. Eligible interventions targeted clinical outcomes (pain, function, disability, fatigue), psychological measures (depression, anxiety), or behavioral outcomes (physical activity, nutrition). All publication types (journal articles, conference abstracts, protocols) published in the English language until January 19, 2025, were considered, and interventions of any duration, frequency, country of origin, or setting (inpatient, outpatient, community, home setting) were included. Two reviewers independently screened studies, and one extracted data on study characteristics, intervention components, AI methodologies, and outcomes. Fifteen AI‐supported interventions were identified, primarily targeting osteoarthritis (73%) and focusing on education and exercise advice (67%). The most common AI tool was rule‐based expert systems (40%), followed by natural language processing systems (33%) and machine learning algorithms (27%). The interventions ranged from 3 weeks to 12 months, whereas sample sizes ranged from 7 to 427 participants, reflecting huge variability across studies. Most interventions demonstrated high usability, engagement, and adherence. Improvements in exercise compliance, physical activity, and symptoms, such as pain and physical function, were reported, though effects varied across studies and were sometimes not sustained long term. AI‐supported interventions show promise in promoting education, exercise, and behavioral guidance for adults with chronic rheumatic diseases. There is evidence for high usability and engagement, but the clinical impact on long‐term symptom management is uncertain.


  • Open Access

    Considerations for Issues of Regression to the Mean and Contextual Effects in Clinical Trials for Pain in Rheumatic Diseases

    by Yen T. Chen, Guohao Zhu, Afton L. Hassett, Daniel Clauw, Susan L. Murphy

    Recently, there has been growing discussion about how to best assess pain in clinical trials in rheumatic diseases. Reliable measurement of pain outcomes is essential for accurately determining the effectiveness of treatments. Although pain intensity is the most common measure of change in pain trials, other pain‐related measures, such as pain interference, are also frequently assessed. Interpreting treatment effects on these outcomes can be complicated due to statistical phenomena, particularly regression to the mean and contextual effects. These issues can substantially distort clinical trial findings, potentially leading to inaccurate conclusions about the efficacy of interventions. The present article provides an overview of regression to the mean and contextual effects, emphasizing their implications for internal validity, clinical decision‐making, and ethical considerations in trials. Additionally, this article highlights key study design and analysis considerations, including methodologic and statistical approaches, that researchers can implement to mitigate or better account for these challenges. Practical recommendations are offered to enhance the rigor of pain assessment, with specific attention to osteoarthritis as a representative example within rheumatic disease research. By recognizing and addressing regression to the mean and contextual effects proactively, researchers can strengthen trial outcomes, improve clinical interpretations, and support the identification of effective treatments.


  • Psychosocial moderators of the association between pain intensity and physical function in people with systemic sclerosis

    by Daniel Whibley, Deeba Minhas, John A Sturgeon, Yen T Chen, Anna Kratz, Dinesh Khanna, Susan L Murphy

    Background: Pain is a prevalent symptom of systemic sclerosis. While previous studies have demonstrated a correlation between higher pain intensity and lower physical function in individuals with systemic sclerosis, the potentially moderating effect of psychosocial factors on the association has yet to be explored. Methods: This cross-sectional study used data from a fatigue self-management trial for adults with systemic sclerosis. Baseline questionnaire instruments measured pain intensity (11-point scale), physical function (PROMIS 4a short form), and psychosocial factors: positive and negative affect (Positive and Negative Affect Schedule), resilience (Connor–Davidson Resilience Scale), anxiety, depression (PROMIS short forms), and self-efficacy domains (PROMIS item banks). Linear regression quantified the pain intensity–physical function association with interaction terms for candidate psychosocial moderators included in separate models (adjusted for age, systemic sclerosis subtype, and disease duration). Results: Among 173 participants (mean age 54.5, Standard Deviation 11.7, 93% female, 83% White), 47% had diffuse cutaneous systemic sclerosis, 35% limited, 13% overlap, and 5% other/unsure. Mean pain intensity was 4.9 (Standard Deviation 2.3) and mean physical function T-score was 38.5 (Standard Deviation 6.4). Pain intensity accounted for 31% of the variability in physical function (B −1.34, 95% confidence interval −1.69, −0.99). Statistically significant interactions were found between pain intensity and negative affect and anxiety, with higher levels of these factors amplifying the negative pain–physical function association. Conclusion: These findings suggest that higher levels of negative affect and anxiety exacerbate the negative effect of pain on physical function in individuals with systemic sclerosis. Interventions targeting these factors may help improve overall physical function regardless of pain intensity.

  • Open Access

    Peer mentoring program through a digital platform for people with systemic sclerosis: A feasibility study

    by Yen T Chen, Nirali Shah, Mary Alore, Sheri Hicks, Nadia Vann, Stephanie Hotz, Adam Pape, Maya Sabbagh, Melissa Cunningham, Dinesh Khanna, et al.

    Objective: People with systemic sclerosis (SSc or scleroderma), a rare chronic autoimmune disease, often face significant physical and emotional challenges. Peer mentoring, where someone with similar lived experiences offers guidance and support, shows promise in enhancing the well-being of recipients and may benefit individuals with systemic sclerosis. This study aims to evaluate the feasibility and potential health effects of peer mentoring through a digital platform for people with systemic sclerosis. Methods: We conducted a one-group study to evaluate a 16-week peer mentoring program for people with systemic sclerosis. Mentors and mentees were matched by demographics and systemic sclerosis characteristics. Feasibility was evaluated using Orsmond and Cohn criteria: recruitment, data collection, acceptability, available resources, and participant responses to the program. Perceptions and usability of the peer mentoring program through a digital platform were assessed at week 16 (post-program). The health effects of peer mentoring were measured at baseline, week 8, and week 16. Results: Five trained mentors and 15 mentees were enrolled. Each mentor was paired with 2–4 mentees. We found that peer mentoring through a digital platform was feasible, acceptable, and had good usability for both mentors and mentees. Mentees reported significantly less anxiety at week 16 ( p < 0.001). Other improvements in fatigue, pain interference, depressed mood, and resilience were observed, but did not reach statistical significance. Conclusion: The peer mentoring program through a digital platform was well-received. Results provided preliminary support for the feasibility and potential health benefits of peer mentoring to enhance well-being in people with systemic sclerosis. Findings lay the groundwork for future peer mentoring research in systemic sclerosis.

  • Open Access

    Peer‐Led Symptom Management Intervention to Enhance Resilience in People With Systemic Sclerosis: Mediation Analysis From a Randomized Clinical Trial

    by Yen T. Chen, Afton L. Hassett, Suiyuan Huang, Dinesh Khanna, Susan L. Murphy

    Objective: Facilitated self‐management interventions have the potential to enhance resilience and well‐being. We examined whether resilience is a mediator of improving physical and psychological symptoms for people with systemic sclerosis (SSc) who participated in a 12‐week online peer‐led symptom management intervention.Methods: We conducted a secondary data analysis from a randomized control trial comparing a peer health‐coached intervention to a waitlist control. Participants completed the Connor‐Davidson Resilience Scale, the Functional Assessment of Chronic Illness Therapy‐Fatigue scale, and the Patient Reported Outcomes Measurement Information System measures of pain interference and depressive symptoms at the baseline and at weeks 6 and 12. Linear mixed effect regression models were used to assess the effect of intervention on changes in resilience. Causal mediation analyses were conducted to examine whether changes in resilience at week 12 mediated intervention effects on changes in fatigue, pain interference, and depressive symptoms at week 12.Results: One hundred and seventy‐three eligible participants were enrolled. Participants in the intervention group reported improvements in resilience (P < 0.001). These changes in resilience mediated the intervention effects on fatigue with indirect effect of −1.41 (95% confidence interval [CI] −2.41 to −0.41), pain interference of −0.86 (95% CI −1.65 to −0.08), and depressive symptoms of −1.99 (95% CI −3.16 to −0.81).Conclusion: For participants in the intervention who had positive improvements in their physical and psychological symptoms, increased resilience was a mechanism for these improvements. These findings support the importance of addressing resilience to improve symptoms in similar SSc interventions.


  • Resilience partially mediates the association between perceived social isolation and life satisfaction in people with systemic sclerosis

    by Yen T Chen, Afton L Hassett, Dinesh Khanna, Susan L Murphy

    Objectives: Systemic sclerosis (SSc) negatively affects quality of life, yet the factors influencing life satisfaction, a key aspect of well-being, remain unclear in this population. Social isolation is common in SSc, potentially linked to decreased life satisfaction, but the underlying mechanisms are unexplored. Resilience, a modifiable psychological resource, may act as a mediator in this relationship among people with SSc. This study aimed to examine the relationship between perceived social isolation and life satisfaction and to investigate whether resilience mediates this relationship. Methods: The Patient-Reported Outcomes Measurement Information System Social Isolation Short Form, the Connor-Davidson Resilience Scale, and the Satisfaction with Life Scale were used to assess perceived social isolation, resilience, and life satisfaction. Linear regressions were conducted using the PROCESS macro for SPSS. Results: Among 163 individuals with SSc who provided complete data at baseline (mean age = 54.7 ± 11.9 years), 47% had diffuse cutaneous SSc, and 57% had an early disease duration. Perceived social isolation was negatively associated with life satisfaction. Resilience partially mediated the association between perceived social isolation and life satisfaction in people with SSc. Conclusions: Findings revealed a significant association between perceived social isolation and life satisfaction and the mediating role of resilience in this association among people with SSc. Results suggest resilience may act as a protective mediator, counteracting the negative influence of perceived social isolation on life satisfaction. Findings support the promotion of social connection and resilience to enhance life satisfaction in people with SSc. Clinical Trials Registration #: NCT04908943


  • Open Access

    Impact of a resilience-building energy management intervention for people with systemic sclerosis: a mixed methods study

    by Yen T Chen, Alexandra E Harper, Tiffany Phanhdone, Mary Alore, Sheri Hicks, Adam Pape, Gina M Jay, Shannen Bolde, Jennie Feldpausch, Timothy C Guetterman, et al.

    Objectives: People with SSc often experience fatigue, which significantly affects daily life functioning and quality of life. We aimed to explore participants’ experiences of a peer health–coached resilience-building energy management to enhance well-being (RENEW) intervention on symptoms and well-being and to use mixed methods to compare how SSc duration influenced the experiences of participants who had clinically significant fatigue improvement vs those who did not. Methods: Semi-structured interviews were conducted with 21 participants from the parent clinical trial randomized to the RENEW intervention. Data were analysed using the rigorous and accelerated data reduction technique combined with thematic content analysis. A mixed methods approach used a joint display to identify themes related to the impact of SSc duration on fatigue improvement status. Participants were categorized into short/improvement, short/limited improvement, long/improvement, and long/limited improvement. Results: Our team generated four themes: participant and peer health–coach relationship, physical and psychological well-being improvement, need for a tailored approach and easy program access through technology. Mixed methods analysis revealed that, regardless of SSc duration, participants with improved fatigue reported increasing self-awareness of SSc-related symptoms and learning coping strategies to manage fatigue. Participants in the short/improvement group reported preferences for slower pacing of the program and pairing with a coach with similar symptom severity. Participants in the long/limited improvement group sought SSc-specific symptom management information. Conclusion: Incorporating peer health coaches and technology is beneficial for self-management interventions for people with SSc. Future tailoring of RENEW based on SSc duration and symptom severity is needed. Clinical trial registration number: clinicatrials.gov, NCT04908943.


  • Open Access

    POS1258 RESULTS FROM A NOMINAL GROUP TECHNIQUE EXERCISE FOR THE CREATION OF A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: THE CRISTAL PROJECT

    by A. Lescoat, Y. Chen, S. L. Murphy, L. Carroll, N. Vann, P. Didio, S. Iya, T. Phanhdone, S. Farrington, Y. Allanore, et al.

    Background The lack of RCTs in limited cutaneous systemic sclerosis (lcSSc) is due, in part, to a paucity of relevant outcome measures to effectively evaluate this subset. This international project, supported by the World Scleroderma Foundation (WSF), Scleroderma &. Raynaud’s UK (SRUK), the Scleroderma Clinical Trial Consortium (SCTC), and the US National Scleroderma Foundation, aims to create a combined response index for lcSSc for use in clinical trials; the CRISTAL index. The most bothersome symptoms from the patients’ perspective were identified through lcSSc patient-centered focus groups [1] and already-identified domains and outcomes were identified through a scoping literature review [2]. Objectives This phase of the overall CRISTAL project aimed to select candidate items for inclusion in a planned longitudinal prospective observational study assessing the psychometric properties of the selected items. We aimed to enrich the list of candidate outcomes from domains identified by the focus groups and scoping review: i) SSc-specific domains (gastro-intestinal involvement, Raynaud’s/microcirculation, musculoskeletal, digital ulcers, pulmonary involvement, cardiac involvement, hand functioning, calcinosis, skin involvement, Sicca syndrome; and ii) general domains (fatigue, pain, cognition, sleep disorder). Methods A two-round international online Delphi exercise was conducted to enrich the list of instruments. Experts in lcSSc were asked to suggest additional items/outcome measures for the domains. Candidate clinician-reported outcomes (ClinROs) and performance outcomes (PerfOs) were selected during a two-day meeting utilizing a nominal group technique (NGT) comprising 3 patient research partners and 8 international experts. Patient research partners received specific-training prior to the NGT meeting to become familiar with the domains, outcomes, and research processes. Results 100 experts were invited to the Delphi exercise and 71 provided answers for at least one round. Participants who provided answers in round 1 were invited to a second Delphi exercise, rating each item on scales (range: 1-9) for feasibility, face validity, content validity, and overall appropriateness for the CRISTAL Index. 59/71 participants provided answers to at least one survey. Items endorsed by more than 50% of the experts were included for discussion at the 2 day-NGT discussion. During the NGT meeting, for each lcSSc specific domain, the list of items selected during Delphi and their characteristics were presented and each voting member was asked to discuss the relevance of these items and to propose new items if important ones were considered missing. Voting members then ranked items from “most appropriate for the CRISTAL index” to “less appropriate”. At the end of each ranking, voting members were asked if they agreed with the ranking; 80% agreement was required to move to the next domain. Across the 10 lcSSc specific domains discussed, a total of 19 items (17 ClinROs and 2 PerfOs) were identified and retained as draft items for testing in the planned observational longitudinal cohort study (Table 1). Conclusion These initial results from the CRISTAL initiative are essential first steps towards the development of a composite index for lcSSc. The next steps will include selection of patient-reported outcomes (PROs) from the PROMIS item bank, existing data in the reported literature, and cognitive debriefing with patients, followed by a prospective cohort study to assess and validate the draft CRISTAL index. References [1]Lescoat A et al. Symptom experience of limited cutaneous systemic sclerosis from the Patients’ perspective: A qualitative study. Semin Arthritis Rheum. 2022 Feb;52:151926. [2]Lescoat A et al. Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: an international collaborative scoping review. Rheumatology (Oxford). 2022 Aug 3;61(8):3132-3148. Acknowledgements This international project was supported by the World Scleroderma Foundation, Scleroderma &. Raynaud’s UK (SRUK), the Scleroderma Clinical Trial Consortium, and the US National Scleroderma Foundation. The authors thank all CRISTAL collaborators. Disclosure of Interests Alain LESCOAT: None declared, Yen Chen: None declared, Susan L Murphy: None declared, Lauryn Carroll: None declared, Nadia Vann: None declared, Paul Didio: None declared, Sarah Iya: None declared, Tiffany Phanhdone: None declared, Sue Farrington Speakers bureau: Boehringer Ingelheim, Galápagos, & Janssen, Yannick Allanore Consultant of: AbbVie, AstraZeneca, Bayer, Boehringer-Ingelheim, Mylan, Janssen, Medsenic, Prometheus, Sanofi, Roche, Grant/research support from: Alpine Immunosciences, Medsenic, OSE Immunotherapeutics, David Cella: None declared, Lorinda Chung Consultant of: Boerhinger Ingelheim, Grant/research support from: Mitsubishi Tanabe, Eicos Sciences, Genentech, Kyverna, and Jannsen., Philip Clements: None declared, Francesco Del Galdo Speakers bureau: Boehringer Ingelheim, Jannsen, AstraZeneca, Consultant of: AstraZeneca, Boehringer Ingelheim, Capella, Chemomab, Jannsen, Mitsubishi-Tanabe, Grant/research support from: Abbvie, AstraZeneca, Boehringer Ingelheim, Capella, Chemomab, Kymab, Jannsen, Mitsubishi-Tanabe, Christopher P Denton: None declared, Oliver Distler Speakers bureau: 4P-Pharma, Abbvie, Acceleron, Alcimed, Altavant, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galderma, Galapagos, Glenmark, Gossamer, iQvia, Horizon, Inventiva, Janssen, Kymera, Lupin, Medscape, Merck, Miltenyi Biotec, Mitsubishi Tanabe, Novartis, Prometheus, Redxpharma, Roivant, Sanofi and Topadur, Consultant of: 4P-Pharma, Abbvie, Acceleron, Alcimed, Altavant, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galderma, Galapagos, Glenmark, Gossamer, iQvia, Horizon, Inventiva, Janssen, Kymera, Lupin, Medscape, Merck, Miltenyi Biotec, Mitsubishi Tanabe, Novartis, Prometheus, Redxpharma, Roivant, Sanofi and Topadur, Grant/research support from: 4P-Pharma, Abbvie, Acceleron, Alcimed, Altavant, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galderma, Galapagos, Glenmark, Gossamer, iQvia, Horizon, Inventiva, Janssen, Kymera, Lupin, Medscape, Merck, Miltenyi Biotec, Mitsubishi Tanabe, Novartis, Prometheus, Redxpharma, Roivant, Sanofi and Topadur, Monqiue Hinchcliff: None declared, Mike Hughes: None declared, Laura Hummers Consultant of: CSL Behring, Boehringer Ingelheim, Abbvie, Ortho-Dermatologics, Grant/research support from: Boehringer Ingelheim, Cumberland Pharmaceuticals, Mitsubishi Tanabe, Horizon Pharmaceuticals, Prometheus Biosciences, John Pauling Speakers bureau: Janssen, Astra Zeneca, Permeatus Inc, Sohournix Pharma, Isomab and Boehringer Ingelheim, Consultant of: Janssen, Astra Zeneca, Permeatus Inc, Sohournix Pharma, Isomab and Boehringer Ingelheim, Janet Pope: None declared, Viginia Steen: None declared, John Varga: None declared, [Peter Merkel]: None declared, Maya H Buch: None declared, Dinesh Khanna Shareholder of: Eicos Sciences, Inc, Consultant of: Acceleron, Amgen, Boehringer Ingelheim, CSL. Behring, Chemomab, Genentech/Roche, Horizon, Mitsubishi. Tanabe Pharma, Prometheus, Talaris and has received grants. from Bayer, BMS, Horizon and Pfizer.